EasyBlog

This is some blog description about this site

UNION therapeutics A/S Announces Global License Agreement with Ceva Santé Animale S.A.

UNION therapeutics A/S (UNION) today announced that it has entered into a strategic veterinary partnership with Ceva Santé Animale S.A. (Ceva) on the candidate UNI836.

Under the agreement, Ceva will be developing UNI836 for treatment of canine pyoderma. Canine pyoderma is one of the most frequent diseases in companion animals and a significant burden for both animal patients and their owners.

Chief Executive Officer of UNION, Dr. Rasmus Toft-Kehler, commented: “We appreciate to be collaborating with one of the fastest growing veterinary care companies on broadening the utility of the compound class. The results generated in collaboration with Ceva indicates that UNI836 has the potential to become a new and highly innovative treatment for companion animals and their owners”. Dr. Morten Sommer, Chief Scientific Officer of UNION, further commented: “Our collaborative efforts have highlighted the novel mechanism of action underlying UNI836 to provide an interesting approach to tackle an unmet medical need in the veterinary space. We look forward to continue working with Ceva on the advancement of UNI836 for treatment of canine pyoderma”.

Dr. Pascal Anjot, VP Global R&D & Innovation, Ceva added: "We are very pleased to be associated with UNION therapeutics for the development of this new opportunity in the treatment of Pyoderma in companion animals. Ceva has long been at the forefront of promoting the rational use of antibiotics in veterinary medicine. The GRAM (Guidance for the Rational use of Antimicrobials) initiative developed together with leading European experts is a good example and this new project with UNION offers to provide veterinarians with a very innovative, therapeutic approach to the treatment of this condition, in line with this aim of continually developing best practice".

As part of the agreement, Ceva will be taking responsibility for further development and global commercialization of UNI836.

About UNION:
UNION is a privately held, clinical stage, pharmaceutical company dedicated to the development of molecules exhibiting both antimicrobial and immunomodulatory effects. The leadership team of UNION has invented and successfully developed more than 10 approved human medicines. In 2018, these medicines saved thousands of lives and generated revenues of more than 5 Billion USD. UNION is headquartered in Copenhagen (Denmark) and managed by a global team across Europe and USA.

About CEVA:
Ceva Santé Animale is a global veterinary health company focused on the research, development, production and marketing of pharmaceutical products and vaccines for companion animals, livestock, swine and poultry. Ceva’s mission summarised in the slogan, "Together, beyond animal health", This document is strictly confidential and not intended for circulation or publication, nor is it to be used, 2 or distributed without prior written consent of UNION therapeutics A/S. Violations may be legally prosecuted. recognises that the future health of animals, humans and our planet are inseparably bound together. Ceva is directly present in 45 countries around the world and have active business in over 110.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of UNION therapeutics A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

UNION Initiates Collaboration with Brown University & Rhode Island Hospital to Fight H. pylori

UNION, a privately held, clinical stage, pharmaceutical company targeting inflammatory and microbiome-related disorders today announced a partnership between Brown University, Rhode Island Hospital and UNION to join forces in the development of a new treatment for Helicobacter pylori. Morten Sommer, CSO at UNION, commented “We are honored and excited to be working with Professor Mylonakis and his group from Brown University to develop a new treatment with great prospects for patients across the world”

H. pylori is one of the world’s most prevalent pathogens and unless treated, colonization usually has lifelong persistence. Most people with H. pylori colonization never experience symptoms, however, each year millions colonized with H. pylori develop gastrointestinal diseases which are also linked to cancer and mortality. Unfortunately, the increase in antibiotic resistance is reducing effective treatment options, hence highlighting the need for new microbiome sparing alternatives.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of UNION therapeutics A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

AntibioTx Enters Collaboration with Southern Illinois University to Tackle Endometriosis

AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced collaboration with Southern Illinois University in the search of new effective treatments against endometriosis. Dr. Rasmus Toft-Kehler CEO at AntibioTx commented “We are excited about the opportunity to collaborate with Dr. Kanako and her group to elucidate the potential for a novel treatment of endometriosis” to which Dr. Morten Sommer, CSO of AntibioTx further added “We have great confidence in the approach invented by Dr. Kanako and are committed to support this program with a clear aim to bring a new treatment to millions of patients with a very significant and neglected medical need”.

Endometriosis is a common long-term chronic disease that can have a profound impact on women’s physical health and quality of life. Symptoms typically appear when endometrial tissue is found outside the uterus causing significant pain and discomfort. Classic symptoms include intense pelvic pain, dysmenorrhea, dyspareunia and infertility. Malignant transformation of endometriosis may occur in up to 1% of women.  

Occurrence is mostly in women of childbearing age and most frequently in the age group 30-40 years. The prevalence is estimated to be 6-10% in the general female population, although the condition is considered to be underdiagnosed.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

AntibioTx Expands Management Team with Dr. Umar Hayat

AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that the company has expanded the management team with Umar Hayat, Ph.D. as VP of CMC and Supply Chain.

Dr. Morten Sommer, Chief Scientific Officer of AntibioTx commented: ”As the company continues to expand into new areas the role of CMC becomes increasingly important for our success. We are delighted to have engaged with such a capacity as Umar and are looking very much forward working with him on the team”

Umar Hayat, Ph.D. will be the VP of CMC and Supply Chain at AntibioTx and will, in particular, be responsible for the late-stage clinical part of CMC. Dr. Hayat has more than 18 years of experience in pharmaceutical development, manufacturing and supply chain. He held senior level positions with Relypsa, Anacor and Transcept Pharmaceuticals. Played a pivotal role in the CMC development and commercialization of Veltassa® (USA and EU), a treatment for hyperkalemia, Intermezzo® for MOTN insomnia, Kerydin® for onychomycosis, and Eucrisa® for atopic dermatitis. Umar received his Ph.D. in process engineering from INP-Toulouse, France and Post-Doctoral Fellowship from Ecole Polytechnique de Montreal, Canada.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

AntibioTx Announces Positive Data Supporting the Safety of ATx201

AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders, has with the addition of two preclinical studies (Ocular Irritation and Phototoxicity) further strengthened ATx201’s safety profile for topical use.

The Ocular Irritation in vitro study evaluated the potential for causing eye damage using gold standard tests. ATx201 2%, 4% and Placebo were all classified as a non-irritant supporting the safety profile of ATx201 with regards to eye contact.

The Phototoxicity in vivo study determined the potential phototoxic effects of ATx201 Gel formulations when administered topically on the skin of hairless mice, followed by exposure to ultraviolet B, ultraviolet A and visible light.

The results provoked no cutaneous phototoxicity following topical dermal administration of the placebo or 2% or 4% ATx201. Dr. Morten Sommer, CSO of AntibioTx concluded: “The safety of ATx201 is of critical importance due to our focus on diseases that are very common in the pediatric population”.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

AntibioTx Strengthens Management Team with CFO and VP of Commercialization

AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that the company has expanded the management team with Morten Boesen as CFO and Mads Jellingso as VP of Commercialization

Dr. Rasmus Toft-Kehler, CEO and Co-founder commented “Strengthening our management team is critical for the company’s continued development and long-term success. What is common for Morten Boesen and Mads Jellingso is that they bring important experience and expertise from globally leading institutions within their respective fields. I am excited that they have decided to join our team at AntibioTx to support the next stage of our venture”.

Morten Boesen will take on the role as Chief Financial Officer, starting from April 1, 2018. Since 2011, Mr. Boesen has worked with EQT, the leading private equity fund in the Nordics, initially as an investment manager and subsequently as an executive director in the EQT-owned global retailer, Tiger. Prior to that, Mr. Boesen worked as a management consultant with McKinsey & Company, in the M&A advisory of Nordea Bank, and in the finance department of Novozymes, the world leader in industrial biotechnology. Mr. Boesen holds a M.Sc. in Finance and Accounting from Copenhagen Business School.

Mads Jellingso will take on the role of Vice President of Commercialization. Mr. Jellingso joins AntibioTx from Novo Nordisk, where he most recently specialized in global market access and innovative contracting. Mr. Jellingso also has experience from the legal affairs and finance departments of Novo Nordisk, and prior to that he worked as a management consultant with McKinsey & Company and management advisor in Nordea Market. Mr. Jellingso holds a M.Sc. in Economics from University of Copenhagen.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

 

Continue reading

FDA Approves IND to Conduct Clinical Studies with ATx201 in USA

AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that the U.S Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) approval of AntibioTx’s ATx201 for treatment of microbiome related skin disorders.

“The FDA approval of our IND is very well-timed since we are ready to initiate studies in North America” said Dr. Lutz Wevelsiep VP of Drug Regulatory Affairs of AntibioTx” The approval to conduct studies in the US has been a key prioritization for a long time and therefore this is a fundamental milestone for AntibioTx”.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

AntibioTx to Present Phase I DECOLAD Results at the 26th EADV

AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders has been invited to present Phase I DECOLAD results at the Annual Congress of the European Academy of Dermatology and Venereology (EADV). The study enrolled 36 healthy volunteers and supported an excellent safety profile of ATx201.

The 26th EADV runs from Wednesday 13 - Sunday 17 of September 2017 in Geneva, Switzerland.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

AntibioTx Announces New Board Members

AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced three new board members. 

Joining AntibioTx board of directors are Stig Loekke Pedersen, Jutta Heim and Ole Skov join the board of directors in AntibioTx.

“We are very pleased to welcome such recognized business and science leaders to AntibioTx”, said Rasmus Toft-Kehler, CEO of AntibioTx and added "These profiles bring a diverse set of knowledge bases to AntibioTx - we are privileged that capacities with such track records join the team to achieve our vision”

Read more about our board of directors here

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

AntibioTx Announces Phase I Study Results for ATx201

AntibioTx, a clinical stage, pharmaceutical company targeting inflammatory and microbiome-related disorders, today declared successful completion of a Phase I study with ATx201. The Study set out to determine the systemic and local exposure of three different formulations of ATx201 in 36 healthy volunteers. “We are pleased about the top-line data which show no signs of unexpected adverse events. Furthermore, pharmacokinetic data from biopsies and plasma samples are very encouraging”, said Rasmus Toft-Kehler, CEO of AntibioTx. CSO, Morten Sommer, further added “These results support the continued development of ATx201 for a variety of skin conditions including atopic dermatitis. We are thankful for the hard work and wanted to express our great appreciation to the clinicians, partners, staff, and volunteers who all contributed significantly to make this study possible”.

About the DECOLAD Phase I Study 
The DECOLAD Phase I study assessed overall safety, local tolerability, pharmacokinetics (PK) in three dermal formulations of ATx201 and was a prospective, randomized, double-blind, placebo controlled study in 36 healthy subjects. Subjects were treated at four separate skin areas, 5 cm in diameter, twice daily with either ATx201 or placebo in a 7-day period. The pharmacokinetic analysis involved blood samples in order to evaluate the systemic exposure and skin biopsies to assess local exposure to the skin. The study was conducted by the Department of Clinical Pharmacology, Medical University of Vienna, Austria.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

AntibioTx Announces Reward of Grant Funding to Conduct Clinical Biomarker Study with ATx201

AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that Antibiotx has been rewarded a grant from Innovation Fund Denmark to further explore ATx201’s influence on biomarkers in inflammatory disease.

Specific inflammatory pathways appear to be important for atopic dermatitis severity and ATx201 shows promising assets affecting these pathways. Based on this rationale, Innovation Fund Denmark has granted AntibioTx the means to investigate ATx201 in a well-established clinical model”.

About Atopic dermatitis
Atopic dermatitis is one of the most common skin diseases - it is estimated that 5–20% of the population worldwide is suffering from atopic dermatitis. The disease is believed to develop from a complex interplay of environmental and immunologic factors and is often associated with allergy and asthma. Characteristic AD symptoms are itchy skin (pruritus) and inflammation causing redness, dry skin, crusting, vesicle formation, and swelling. Numerous studies have found that AD has a major impact on physical and psychological well-being and has a negative psychological impact on close relatives.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Source: Thomas Bieber. Atopic Dermatitis, Mechanisms of Disease. New England Journal of Medicine, 2008

Continue reading

AntibioTx Expands Management Team with new VP of Drug Regulatory Affairs

AntibioTx, a clinical stage, pharmaceutical company targeting microbiome-related disorders today announced that Lutz Wevelsiep, Ph.D. will be appointed as AntibioTx new VP of Drug Regulatory Affairs.

“Lutz will manage and oversee the Company’s international filings and relations with regulatory authorities” said Rasmus Toft-Kehler, CEO of AntibioTx ”Lutz brings more than 25 years’ of experience and has a proven track record from both multinational and start-up companies thus we feel confident that we have found the right person in charge of our overall regulatory strategies”. 

Dr. Wevelsiep has been Head of Global Regulatory Affairs for 16 years at Basilea Pharmaceutica. His track record includes successful completion of the European marketing authorization applications for Isavuconazole (Cresmba®), Ceftobiprole (Zevtera®) and Alitretinoin (Toctino®). Lutz holds a Ph.D. and Postdoc in chemistry from the Max-Planck Institute in Germany.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

AntibioTx Invited to Present at Berlin Antimicrobial Conference

Worldwide we a see a need for action against AMR and AntibioTx is highly aware of something has to be done. The 10th Berlin Conference on Life Sciences takes place 24th February 2017. 
The conference will focus on the problems we face combating AMR; such as the need for new R&D and improve clinical, financial and approval pathway in order to safeguard healthcare in the future.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

AntibioTx Concludes 28-day Repeat Dosing in Göttingen Minipigs with Positive Results

A 28-day repeat dosing study in Göttingen minipigs concluded that proprietary formulations of ATx201 are well tolerated and leads to very low systemic exposure. BioAdvice, a leading GLP and GMP contract research organization located in Denmark, conducted the study. The outcome confirms previous studies suggestive of the favorable safety profile of ATx201.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

AntibioTx Invited to Publish ATx201 Results at the ‘2nd Inflammatory Skin Disease Summit’ (New York)

AntibioTx has been invited to present recent positive results with ATx201 at the ‘2nd Inflammatory Skin Disease Summit’ symposium in New York the 16-20th November 2016. 

The ‘2nd Inflammatory Skin Disease Summit’ is a symposium that directly addresses and describes new developments and therapies for key inflammatory skin diseases, such as psoriasis, atopic dermatitis and an increasing number of other inflammatory conditions. 

The main purpose of the symposium is to update practicing dermatologist, MD-scientists and researchers in the field of treating skin diseases. The Symposium will feature internationally recognized researchers and will provide new research within skin infections and guidelines for future treatments improving clinical outcomes for the patients.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

AntibioTx Enters Collaboration with Dr. Keith Bostian to Establish Medicinal Chemistry Program

Dr. Keith Bostian is a well-renowned figure within science of medicine and has extensive experience with biotechnology industry entrepreneurship and has had executive operating roles in companies financed by leading venture firms within biotechnology. 

Morten Sommer, CSO of AntibioTx commented: ”I’m looking very much forward to the collaboration with Dr. Keith Bostian and have strong confidence that Keith will further help to accelerate recent progress on our chemistry platform to develop new chemical entities for treatment of unmet medical needs”.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

In vivo Efficacy Studies of ATx201 Compares Favorably with Marketed Products

Recent in vivo studies in mice documents the antibacterial properties of ATx201 and that they compare favorably to marketed products. The CSO of AntibioTx, Dr. Morten Sommer, said “ATx201 looks promising in numerous points such as treatment duration, de novo resistance and effectiveness against multi-drug resistant bacteria including MRSA. We strongly believe that ATx201 will be a valuable asset in treating microbiome related disorders”.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

Horizon2020 Grant Awarded to Consortium (Train2Target) Comprising AntibioTx

AntibioTx and the Train2Target consortium, comprising leading academic groups and SME’s in the antimicrobial space, has been awarded a Horizon2020 grant to fund research and development. The grant will focus on antimicrobial resistance and in particular how to harness the challenges of the increasing problem with antibiotic resistance. Through the grant, AntibioTx will offer a PhD-position to a top-talented microbiologist who is passionate about the development of new antibacterial medicines.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

Collaboration Initiated with Prof. Mylonakis (Brown University) to Further Elucidate MoA and New Indication Opportunities

AntibioTx welcomes the collaboration with Professor Mylonakis and foresees it as a very important step towards extracting the compound class potentials. 

Professor Mylonakis is an expert in molecular biology, biostatistics, microbial and pathogenesis, which he often combines with a pragmatic problem-solving approach such as developing methods and strategies against antimicrobial resistance.

Professor Mylonakis is currently chief of the Infectious Diseases Division and Dean’s Professor of Medicine at the Warren Alpert Medical School of Brown. He has published more than 200 peer-reviewed scientific articles edited five books and has been on the editorial board of 10 scientific and peer-reviewed journals. 
Mylonakis has received several awards for his research, counting awards from the American Society for Microbiology and the Infectious Disease Society of America.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

In vivo Study in Minipigs Confirmed Systemic Safety and No Genotoxicity of ATx201

AntibioTx detected no systemic availability of ATx201 after the application in Hanford minipigs. The study protocol consisted of applying ATx201 twice a day for 28-days, followed by a 28-day recovery period to ensure no detectable genotoxicity.

The study was conducted by researchers at the In-Life Testing Facility at Sinclair Research Center, LLC - located in Missouri, USA. Sinclair Research is specialized in preclinical studies and has broad experience in applied human and veterinary models.

Dr. Morten Sommer, CSO of AntibioTx, commented: “We are pleased about the outcome of the minipig study which supports further development of ATx201”.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Continue reading

News